Teriflunomide (Aubagio®) for the treatment of multiple sclerosis

被引：37
作者：
Bar-Or, Amit [1 ,2 ,3 ]
机构：
[1] McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada
[2] McGill Univ, Montreal Neurol Inst, Expt Therapeut Program, Montreal, PQ H3A 2B4, Canada
[3] McGill Univ, Montreal Neurol Inst, Clin Res Unit, Montreal, PQ H3A 2B4, Canada
来源：
EXPERIMENTAL NEUROLOGY | 2014年 / 262卷
关键词：
Multiple sclerosis; Immune modulation; Treatment; Aubagio; Teriflunomide; Leflunomide; AGOUTI RAT MODEL; DE-NOVO SYNTHESIS; PHASE-III TRIAL; ORAL TERIFLUNOMIDE; IMMUNOMODULATORY DRUG; RHEUMATOID-ARTHRITIS; T-LYMPHOCYTES; LEFLUNOMIDE; SAFETY; CELLS;
D O I：
10.1016/j.expneurol.2014.06.005
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Teriflunomide (Aubagio) is a once-daily oral immunomodulatory disease modifying therapy (DMT) presently approved in several regions, including Europe, North America, Latin America and Australia, for the treatment of relapsing forms of multiple sclerosis (RMS; RRMS). The therapeutic mode of action of teriflunomide in MS continues to be investigated. This review summarizes the main efficacy and safety results of the clinical trial program leading to teriflunomide's approval, highlights a number of practical clinical considerations, and overviews its presumed therapeutic mode of action (MOA) based on pharmacokinetic and pharmacodynamic observations and the growing body of teriflunomide-related in vitro, pre-clinical (animal model), and in vivo human studies. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码：57 / 65
页数：9
相关论文
共 52 条
[1]  
Bar-Or A, 2013, MULT SCLER J, V19, P74
[2]   Teriflunomide and Its Mechanism of Action in Multiple Sclerosis [J].
Bar-Or, Amit ;
Pachner, Andrew ;
Menguy-Vacheron, Francoise ;
Kaplan, Johanne ;
Wiendl, Heinz .
DRUGS, 2014, 74 (06) :659-674
[3]   Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis [J].
Bar-Or, Amit ;
Freedman, Mark S. ;
Kremenchutzky, Marcelo ;
Menguy-Vacheron, Francoise ;
Bauer, Deborah ;
Jodl, Stefan ;
Truffinet, Philippe ;
Benamor, Myriam ;
Chambers, Scott ;
O'Connor, Paul W. .
NEUROLOGY, 2013, 81 (06) :552-558
[4]   Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis [J].
Bielekova, B ;
Sung, MH ;
Kadom, N ;
Simon, R ;
McFarland, H ;
Martin, R .
JOURNAL OF IMMUNOLOGY, 2004, 172 (06) :3893-3904
[5]   Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide [J].
Bruneau, JM ;
Yea, CM ;
Spinella-Jaegle, S ;
Fudali, C ;
Woodward, K ;
Robson, PA ;
Sautès, C ;
Westwood, R ;
Kuo, EA ;
Williamson, RA ;
Ruuth, E .
BIOCHEMICAL JOURNAL, 1998, 336 :299-303
[6]   Teriflunomide for the Treatment of Relapsing Multiple Sclerosis: A Review of Clinical Data [J].
Brunetti, Luigi ;
Wagner, Mary L. ;
Maroney, Megan ;
Ryan, Melody .
ANNALS OF PHARMACOTHERAPY, 2013, 47 (09) :1153-1160
[7]  
CHERWINSKI HM, 1995, J PHARMACOL EXP THER, V275, P1043
[8]   Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Confavreux, Christian ;
O'Connor, Paul ;
Comi, Giancarlo ;
Freedman, Mark S. ;
Miller, Aaron E. ;
Olsson, Tomas P. ;
Wolinsky, Jerry S. ;
Bagulho, Teresa ;
Delhay, Jean-Luc ;
Dukovic, Deborah ;
Truffinet, Philippe ;
Kappos, Ludwig .
LANCET NEUROLOGY, 2014, 13 (03) :247-256
[9]   Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years [J].
Confavreux, Christian ;
Li, David K. ;
Freedman, Mark S. ;
Truffinet, Philippe ;
Benzerdjeb, Hadj ;
Wang, Dazhe ;
Bar-Or, Amit ;
Traboulsee, Anthony L. ;
Reiman, Lucy E. ;
O'Connor, Paul W. .
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (09) :1278-1289
[10]   Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation [J].
Dimitrova, P ;
Skapenko, A ;
Herrmann, ML ;
Schleyerbach, R ;
Kalden, JR ;
Schulze-Koops, H .
JOURNAL OF IMMUNOLOGY, 2002, 169 (06) :3392-3399
123456